Characteristics of the enrolled patients with sCAEBV disease
| Patient number . | Sex . | Age (y) . | EBV-infected cells . | Ruxolitinib initiation . | Treatment before ruxolitinib . | HSCT . | |||
|---|---|---|---|---|---|---|---|---|---|
| Clonality of the infected cells . | Disease activity symptom(s) . | Other clinical findings . | EBV-DNA (copies per 103/μL DNA) . | ||||||
| I-1 | M | 13 | CD56 | Monoclonal | Liver dysfunction | Coronary aneurysm | 710∗ | (−) | (+) |
| II-1 | M | 46 | CD56 | Monoclonal | Liver dysfunction | ND | 2 400∗ | (−) | (−) |
| II-2 | F | 40 | CD56 | Monoclonal | Liver dysfunction | ND | 1 200∗ | CHOP × 2, Cytarabine 150 mg/d ×7 d | (+) |
| II-3 | F | 24 | CD8 | Monoclonal | Fever | ND | 0.89 | mPSL pulse, VP16 ＋ PSL, DeVIC, SMILE | (+) |
| II-4 | F | 64 | CD56 | Monoclonal | Liver dysfunction | ND | 51 | (−) | (+) |
| II-5 | M | 63 | CD4 | Monoclonal | Fever, liver dysfunction, progressive skin lesions | ND | 8.4 | (−) | (+) |
| III-1 | M | 33 | CD4 | Monoclonal | Fever | ND | 0.43 | (−) | (+) |
| III-4 | M | 49 | CD4 | Monoclonal | Fever, liver dysfunction | ND | 2 | (−) | (−) |
| III-6 | F | 21 | CD4 | Monoclonal | Fever | Cerebral aneurysm | 37 | CHOP ×3 | (+) |
| Patient number . | Sex . | Age (y) . | EBV-infected cells . | Ruxolitinib initiation . | Treatment before ruxolitinib . | HSCT . | |||
|---|---|---|---|---|---|---|---|---|---|
| Clonality of the infected cells . | Disease activity symptom(s) . | Other clinical findings . | EBV-DNA (copies per 103/μL DNA) . | ||||||
| I-1 | M | 13 | CD56 | Monoclonal | Liver dysfunction | Coronary aneurysm | 710∗ | (−) | (+) |
| II-1 | M | 46 | CD56 | Monoclonal | Liver dysfunction | ND | 2 400∗ | (−) | (−) |
| II-2 | F | 40 | CD56 | Monoclonal | Liver dysfunction | ND | 1 200∗ | CHOP × 2, Cytarabine 150 mg/d ×7 d | (+) |
| II-3 | F | 24 | CD8 | Monoclonal | Fever | ND | 0.89 | mPSL pulse, VP16 ＋ PSL, DeVIC, SMILE | (+) |
| II-4 | F | 64 | CD56 | Monoclonal | Liver dysfunction | ND | 51 | (−) | (+) |
| II-5 | M | 63 | CD4 | Monoclonal | Fever, liver dysfunction, progressive skin lesions | ND | 8.4 | (−) | (+) |
| III-1 | M | 33 | CD4 | Monoclonal | Fever | ND | 0.43 | (−) | (+) |
| III-4 | M | 49 | CD4 | Monoclonal | Fever, liver dysfunction | ND | 2 | (−) | (−) |
| III-6 | F | 21 | CD4 | Monoclonal | Fever | Cerebral aneurysm | 37 | CHOP ×3 | (+) |
HSCT, Hematopoietic stem cell transplantation; CHOP, cyclophosphamide; doxorubicin; vincristine; prednisolone; DeVIC, dexamethasone; etoposide; ifosfamide; carboplatin; F, female; M, male; ND, not detected; PSL, prednisolone; SMILE, dexamethasone; etoposide; ifosfamide; methotrexate; L-asparaginase.
EBV-DNA quantitative levels were measured at an alternative laboratory, SRL, Inc. The units were copies per mL.